![Response to IST and clonal evolution to MDS/AML in patients with AA with or without HLA− cells. (A) The distribution of the HLA− granulocyte percentages in AA patients with HLA− cells. Red bars indicate the median clone size. (B) The distribution of the GPI− granulocyte percentages in AA patients with GPI− cells. (C) The response to IST in AA patients with or without HLA− cells. *A significant difference P < .05. (D) The cumulative incidence of clonal evolution to MDS/AML in the overall population of patiens with AA. (E) The cumulative incidence of clonal evolution to MDS/AML in AA patients with (red line) or without (black line) HLA− cells. (F) The pie diagram indicates the proportions of concomitant aberrant clones detected in 127 patients with AA with HLA− cells. The bar graphs depict the number of patients with AA with HLA− cells and concomitant aberrant clones. (G) The pie diagrams indicates the proportions of HLA− cells and concomitant aberrant clones in 2 representative cases (unique patient number [UPN] 313 and UPN 631).](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/137/25/10.1182_blood.2020010586/2/bloodbld2020010586f1.png?Expires=1720801988&Signature=k5o5SScyVoCMfomTI5BcRA9qdSYVIT25BeMERrduGGMOzW7M7T6xP4pR8yySt0jStGoAGG32MRs-c12kzp5pJ4gKwiZjOWgLEkc63sFJ0fmxehrok87VUqy3SKJmK4VuH9ifs115wcGoo083QGkg7ZtJIZJlYjQv02rmNLVn7YsqPq4uWxtuG1PiuiCvc9XG9qZhFzoTG3OJzxynOJ8xkwW7O8kxjGE48GDlZr6Bwg03KRDnASBCmv~mIx-RKA-qRk3eRmpdcWZo4A93KvH0ICl-iUDsbuTHc0TIBSC3Ng-gZI2KOOD7WSpc22UHX2anO1rtDWE2P3uXiO5DRlHftA__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Response to IST and clonal evolution to MDS/AML in patients with AA with or without HLA− cells. (A) The distribution of the HLA− granulocyte percentages in AA patients with HLA− cells. Red bars indicate the median clone size. (B) The distribution of the GPI− granulocyte percentages in AA patients with GPI− cells. (C) The response to IST in AA patients with or without HLA− cells. *A significant difference P < .05. (D) The cumulative incidence of clonal evolution to MDS/AML in the overall population of patiens with AA. (E) The cumulative incidence of clonal evolution to MDS/AML in AA patients with (red line) or without (black line) HLA− cells. (F) The pie diagram indicates the proportions of concomitant aberrant clones detected in 127 patients with AA with HLA− cells. The bar graphs depict the number of patients with AA with HLA− cells and concomitant aberrant clones. (G) The pie diagrams indicates the proportions of HLA− cells and concomitant aberrant clones in 2 representative cases (unique patient number [UPN] 313 and UPN 631).